EMA to Review Diabetic Ketoacidosis Risk With SGLT2 InhibitorsEMA to Review Diabetic Ketoacidosis Risk With SGLT2 Inhibitors

The European Medicines Agency reports 101 cases of diabetic ketoacidosis associated with use of SGLT2 inhibitors for treatment of type 2 diabetes, begins review to see if any change to use required. News Alerts
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news